FeesSafety
Pluang+

Tesla holds 11,509 BTC, reports $112M impairment loss amid Q2 bitcoin price drop and mixed earnings.

Market News
22 Jul 2026, 23:40 WIB
Coindesk
View Source
Neutral
Tesla holds 11,509 BTC, reports $112M impairment loss amid Q2 bitcoin price drop and mixed earnings.

Tesla maintained its bitcoin holdings at 11,509 BTC through Q2 2026 despite a 14% bitcoin price drop, resulting in a $112 million after-tax impairment loss. The company reported mixed Q2 financial results, beating revenue estimates with $28.2 billion but missing profit expectations with adjusted EPS of $0.33. Tesla has not bought or sold bitcoin since 2022 and remains one of the largest public corporate bitcoin holders. The impairment loss reflects accounting rules requiring companies to recognize declines in digital asset values during the reporting period.

More News

EssilorLuxottica reports total shares and voting rights as of October 31, 2026, with a 31% voting cap per shareholder.

EssilorLuxottica reports total shares and voting rights as of October 31, 2026, with a 31% voting cap per shareholder.

As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...

Company Fundamentals
Neutral
1 hour ago
EssilorLuxottica reports 464 million shares and voting rights as of October 31, 2026, with a 31% voting cap.

EssilorLuxottica reports 464 million shares and voting rights as of October 31, 2026, with a 31% voting cap.

EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...

Company Fundamentals
Neutral
1 hour ago
Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...

Bullish
2 hours ago
Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...

Others
Bullish
2 hours ago
New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...

Others
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App